New!!!  September 14, 2017 – Revolutionary Immunotherapy: CAR T-Cell Therapy    “Imagine being able to program your immune system to launch one million minuscule heat-seeking missiles, whose sole purpose is to find and kill cancer cells.  This is the basic premise behind an emerging form of immunotherapy, called CAR T-cell therapy, which genetically modifies an individual’s immune system to find, bind to, and kill cancer cells.”

July 2017 – Clinical trial evaluating the efficacy and safety of an investigative drug for Lung Neuroendocrine Tumors (Lung NETs)
“This is a Phase 3, prospective, multi-center, randomized, double-blind, study evaluating the efficacy and safety of LAN plus BSC versus placebo plus BSC for the treatment of well-differentiated, metastatic and/or unresectable, typical or atypical lung NETs.  … The primary objective will be to compare the antitumour efficacy of Lanreotide Autogel/Depot 120 mg (LAN) plus Best Supportive Care (BSC) every 28 days versus placebo plus BSC, in terms of progression free survival (PFS), measured by central review using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria, every 12 weeks, in subjects with unresectable and/or metastatic well differentiated, typical or atypical lung neuroendocrine tumours” search results on lung+Carcinoid search results on neuroendocrine+tumors

Current Oncology 2006 article “Guidelines for the diagnosis and management of carcinoid tumours.  Part 1: The gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group

NET Research Foundation list of “notable research results” (2005 – 2015)

A 5-decade analysis of 13,715 carcinoid tumors, February 3, 2003